Abstract：Objective To explore the clinical effect of panretinal photocoagulation combined with Ranibizumab treating severe non-proliferative diabetic retinopathy (DR). Methods A total of 96 patients with severe non-proliferative DR admitted to Shangrao Aier Eye Hospital from August 2019 to August 2020 were selected as the research objects and divided to the control group (48 cases) and the study group (48 cases) according to the random ballot method. The control group was treated with panretinal photocoagulation, and the study group was treated with panretinal photocoagulation combined with Ranibizumab. The clinical efficacy, best corrected visual acuity (BCVA), intraocular pressure (IOP),central macular thickness (CMT) and adverse reactions were compared between the two groups. Results The total effective rate in the study group was higher than that in the control group, the difference was statistically significant (P<0.05).There was no significant difference in BCVA between the two groups before treatment (P>0.05). After treatment, the BCVA of the study group lower than that of the control group, the difference was statistically significant (P<0.05). There were no significant differences in IOP and CMT between the two groups before treatment (P>0.05). After treatment, the IOP and CMT of the study group were lower than those of the control group, the differences were statistically significant(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Panretinal photocoagulation combined with Ranibizumab could effectively improve the vision of patients with severe non-proliferative DR, reduce IOP and CMT. It has certain clinical effect.
Bressler SB，Beaulieu WT，Glassman AR，et al.Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy：Factors Associated with Vision and Edema Outcomes[J].Ophthalmology，2018，125（11）：1776-1783.
京公网安备 11010502046607号